Biotech | August 06, 2024
Lupin completes successful Phase 3 trials for Lucentis biosimilar
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Revolutionary technology will further boost OneSource’s scientific services offerings
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Subscribe To Our Newsletter & Stay Updated
